Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 6/2013

01.12.2013 | Gynecologic Oncology

The influence of early diagnosis of endometrioid endometrial cancer on disease stage and survival

verfasst von: Frida Barak, Leonid Kalichman, Michael Gdalevich, Ronny Milgrom, Yael Laitman, Benjamin Piura, Ofer Lavie, Ofer Gemer

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Objective

To evaluate whether the presence or duration of uterine bleeding is associated with disease stage, and survival of patients with endometrioid endometrial carcinoma (EEC).

Methods

The records of 220 patients with EEC who underwent surgery were reviewed. The patients were divided into three groups according to the presence and duration of vaginal bleeding at the time of surgery. Group 1, without vaginal bleeding; group 2, vaginal bleeding up to 3 months; group 3, vaginal bleeding exceeding 3 months prior to surgery. Disease stage and survival were between the three groups.

Results

Of the 220 patients, 42 (19 %) were asymptomatic; 95 (43 %) had symptom duration of up to 3 months and 83 (38 %) experienced bleeding for >3 months. There were no significant differences between groups 1, 2 and 3 regarding the proportion of patients with deep invasion in stage I (21, 24, 26 %, p = 0.84; respectively), with grade 3 tumors (10, 13, 14 %, p = 0.42; respectively) or with advanced stage disease (12, 14, 15 %, p = 0.92; respectively). Survival analysis demonstrated a non-significant trend toward better survival in asymptomatic patients and in patients with a shorter duration of symptoms (p = 0.172).

Conclusions

Diagnosis of EEC in asymptomatic patients or in patients with a short duration of bleeding is associated with comparable stage and survival.
Literatur
1.
Zurück zum Zitat Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I (2005) Endometrial cancer. Lancet 366:491–505PubMedCrossRef Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I (2005) Endometrial cancer. Lancet 366:491–505PubMedCrossRef
2.
Zurück zum Zitat Plataniotis G (2010) Castiglione M; ESMO Guidelines Working Group. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 5:41–45CrossRef Plataniotis G (2010) Castiglione M; ESMO Guidelines Working Group. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 5:41–45CrossRef
3.
Zurück zum Zitat Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL et al (2006) Carcinoma of the corpus uteri. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95:S105–S143PubMedCrossRef Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL et al (2006) Carcinoma of the corpus uteri. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95:S105–S143PubMedCrossRef
4.
Zurück zum Zitat Jacobs I, Gentry-Maharaj A, Burnell M, Manchanda R, Singh N, Sharma A et al (2011) Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol 12:38–48PubMedCrossRef Jacobs I, Gentry-Maharaj A, Burnell M, Manchanda R, Singh N, Sharma A et al (2011) Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol 12:38–48PubMedCrossRef
5.
Zurück zum Zitat Obermair A, Hanzal E, Schreiner-Frech I, Buxbaum P, Bancher-Todesca D, Thoma M, Kurz C, Vavra N, Gitsch G, Sevelda P (1996) Influence of delayed diagnosis on established prognostic factors in endometrial cancer. Anticancer Res 16(2):947–949PubMed Obermair A, Hanzal E, Schreiner-Frech I, Buxbaum P, Bancher-Todesca D, Thoma M, Kurz C, Vavra N, Gitsch G, Sevelda P (1996) Influence of delayed diagnosis on established prognostic factors in endometrial cancer. Anticancer Res 16(2):947–949PubMed
6.
Zurück zum Zitat Menczer J, Krissi H, Chetrit A, Gaynor J, Lerner L, Ben-Baruch G et al (1995) The effect of diagnosis and treatment delay on prognostic factors and survival in endometrial carcinoma. Am J Obstet Gynecol 173:774–778PubMedCrossRef Menczer J, Krissi H, Chetrit A, Gaynor J, Lerner L, Ben-Baruch G et al (1995) The effect of diagnosis and treatment delay on prognostic factors and survival in endometrial carcinoma. Am J Obstet Gynecol 173:774–778PubMedCrossRef
7.
Zurück zum Zitat Osmers RG, Osmers M, Kuhn W (1995) Prognostic value of transvaginal sonography in asymptomatic endometrial cancers. Ultrasound Obstet Gynecol 6:103–107PubMedCrossRef Osmers RG, Osmers M, Kuhn W (1995) Prognostic value of transvaginal sonography in asymptomatic endometrial cancers. Ultrasound Obstet Gynecol 6:103–107PubMedCrossRef
8.
Zurück zum Zitat Gerber B, Krause A, Muller H, Reimer T, Kulz T, Kundt G (2001) Ultrasonographic detection of asymptomatic endometrial cancer in postmenopausal patients offers no prognostic advantage over symptomatic disease discovered by uterine bleeding. Eur J Cancer 37:64–71PubMedCrossRef Gerber B, Krause A, Muller H, Reimer T, Kulz T, Kundt G (2001) Ultrasonographic detection of asymptomatic endometrial cancer in postmenopausal patients offers no prognostic advantage over symptomatic disease discovered by uterine bleeding. Eur J Cancer 37:64–71PubMedCrossRef
9.
Zurück zum Zitat Kimura T, Kamiura S, Yamamoto T, Seino-Noda H, Ohira H, Saji F (2004) Abnormal uterine bleeding and prognosis of endometrial cancer. Int J Gynaecol Obstet 85:145–150PubMedCrossRef Kimura T, Kamiura S, Yamamoto T, Seino-Noda H, Ohira H, Saji F (2004) Abnormal uterine bleeding and prognosis of endometrial cancer. Int J Gynaecol Obstet 85:145–150PubMedCrossRef
10.
Zurück zum Zitat Seebacher V, Schmid M, Polterauer S, Hefler-Frischmuth K, Leipold H, Concin N et al (2009) The presence of postmenopausal bleeding as prognostic parameter in patients with endometrial cancer: a retrospective multi-center study. BMC Cancer 9:460PubMedCrossRef Seebacher V, Schmid M, Polterauer S, Hefler-Frischmuth K, Leipold H, Concin N et al (2009) The presence of postmenopausal bleeding as prognostic parameter in patients with endometrial cancer: a retrospective multi-center study. BMC Cancer 9:460PubMedCrossRef
11.
Zurück zum Zitat Levy T, Golan A, Menczer J (2006) Endometrial endometrioid carcinoma: a glimpse at the natural course. Am J Obstet Gynecol 195:454–457PubMedCrossRef Levy T, Golan A, Menczer J (2006) Endometrial endometrioid carcinoma: a glimpse at the natural course. Am J Obstet Gynecol 195:454–457PubMedCrossRef
Metadaten
Titel
The influence of early diagnosis of endometrioid endometrial cancer on disease stage and survival
verfasst von
Frida Barak
Leonid Kalichman
Michael Gdalevich
Ronny Milgrom
Yael Laitman
Benjamin Piura
Ofer Lavie
Ofer Gemer
Publikationsdatum
01.12.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 6/2013
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-013-2898-5

Weitere Artikel der Ausgabe 6/2013

Archives of Gynecology and Obstetrics 6/2013 Zur Ausgabe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Menopausale Hormontherapie für Frauen über 65?

07.05.2024 Klimakterium und Menopause Nachrichten

In den USA erhalten nicht wenige Frauen auch noch im Alter über 65 eine menopausale Hormontherapie. Welche positiven und negativen gesundheitlichen Konsequenzen daraus möglicherweise resultieren, wurde anhand von Versicherungsdaten analysiert.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.